Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
This article was originally published in The Gray Sheet
Executive Summary
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
You may also be interested in...
Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%
Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter
Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%
Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter
Biomet Accepts $10.9 Bil. Private Equity Buyout To Stay Independent
Orthopedic device makers Smith & Nephew and Biomet ended discussions on a possible merger after Biomet announced plans to become a private, independent company by the end of October